Uy Ear
Stock Analyst at Mizuho
(3.23)
# 1,183
Out of 4,420 analysts
51
Total ratings
40.62%
Success rate
5.03%
Average return
Main Sectors:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $20 → $18 | $13.25 | +35.85% | 1 | Apr 26, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Neutral | $39 → $25 | $17.00 | +47.06% | 9 | Mar 12, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $13.39 | +71.77% | 3 | Mar 8, 2024 | |
| QURE uniQure | Maintains: Neutral | $10 → $7 | $4.72 | +48.31% | 2 | Mar 4, 2024 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | $16 → $17 | $7.95 | +113.84% | 10 | Feb 28, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $130 → $145 | $135.04 | +7.38% | 4 | Feb 14, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $141.71 | -1.21% | 10 | Feb 8, 2024 | |
| AVRO AVROBIO | Downgrades: Neutral | $5 → $2 | $1.24 | +61.29% | 3 | Dec 18, 2023 | |
| RVNC Revance Therapeutics | Maintains: Buy | $35 → $16 | $4.10 | +290.24% | 1 | Nov 22, 2023 | |
| ALKS Alkermes | Maintains: Buy | $37 → $35 | $24.10 | +45.23% | 4 | Oct 26, 2023 | |
| JNJ Johnson & Johnson | Maintains: Buy | $36 → $40 | $148.58 | -73.08% | 1 | Jun 7, 2023 | |
| CABA Cabaletta Bio | Reiterates: Buy | $10 | $12.86 | -22.24% | 1 | Mar 17, 2023 | |
| OCGN Ocugen | Maintains: Buy | $5 → $3 | $1.63 | +84.05% | 2 | Mar 1, 2023 |
Sage Therapeutics
Apr 26, 2024
Maintains: Neutral
Price Target: $20 → $18
Current: $13.25
Upside: +35.85%
ACADIA Pharmaceuticals
Mar 12, 2024
Downgrades: Neutral
Price Target: $39 → $25
Current: $17.00
Upside: +47.06%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $13.39
Upside: +71.77%
uniQure
Mar 4, 2024
Maintains: Neutral
Price Target: $10 → $7
Current: $4.72
Upside: +48.31%
Arcutis Biotherapeutics
Feb 28, 2024
Reiterates: Buy
Price Target: $16 → $17
Current: $7.95
Upside: +113.84%
Sarepta Therapeutics
Feb 14, 2024
Maintains: Buy
Price Target: $130 → $145
Current: $135.04
Upside: +7.38%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $141.71
Upside: -1.21%
AVROBIO
Dec 18, 2023
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.24
Upside: +61.29%
Revance Therapeutics
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $4.10
Upside: +290.24%
Alkermes
Oct 26, 2023
Maintains: Buy
Price Target: $37 → $35
Current: $24.10
Upside: +45.23%
Johnson & Johnson
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $148.58
Upside: -73.08%
Cabaletta Bio
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $12.86
Upside: -22.24%
Ocugen
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.63
Upside: +84.05%